Nevertheless, one representative of this class of PD-1/PD-L1 inhibitors, MAX 10129, showed encouraging results in preclinical studies, e.g., anti-tumor efficacy in combination with an anti-CTLA4 antibody, and reportedly is undergoing further development towards clinical trials. The gene discussed is CTLA4; the disease is neoplasm.